The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.

Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA13 Dec 2011Cited by 95 (Europe PMC)

PMID22159672DOI10.1007/s00198-011-1856-yPepBankPUB-22159672

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, teriparatide and risedronate produced similar worst-back-pain responder proportions at 6 months.
In plain wordsTeriparatide and risedronate produced similar proportions of women with reduced worst back pain at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAt least 30% reduction in worst back pain at 6 months
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Analysis
Primary
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Pain responders
59%
teriparatide
Pain responders
57%
risedronate
Source sentences
Summary
At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary objective was to compare the proportion of subjects reporting ≥30% reduction in worst back pain severity from baseline to 6 months as assessed by a numeric rating scale in each treatment group.
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967201
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, worst-back-pain response did not differ between teriparatide and risedronate at any assessed time.
In plain wordsWorst back pain response did not differ between teriparatide and risedronate at any assessed time.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeWorst back pain response across time points
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life.
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967202
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, average-back-pain response did not differ between teriparatide and risedronate.
In plain wordsAverage back pain response did not differ between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAverage back pain response
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life.
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967203
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, disability did not differ between teriparatide and risedronate.
In plain wordsDisability did not differ between teriparatide and risedronate in women with vertebral fractures.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDisability
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life.
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967204
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, quality of life did not differ between teriparatide and risedronate.
In plain wordsQuality of life did not differ between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeQuality of life
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Quality of life · Whole body
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life.
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967205
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, teriparatide increased lumbar spine BMD more than risedronate.
In plain wordsTeriparatide increased spine bone density more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
There was a greater increase from baseline in bone mineral density at the lumbar spine (p = 0.001) and femoral neck (p = 0.02) with teriparatide compared to risedronate and a lower incidence of vertebral fractures at 18 months (4% teriparatide and 9% risedronate; p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967206
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, teriparatide increased femoral neck BMD more than risedronate.
In plain wordsTeriparatide increased hip bone density more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
There was a greater increase from baseline in bone mineral density at the lumbar spine (p = 0.001) and femoral neck (p = 0.02) with teriparatide compared to risedronate and a lower incidence of vertebral fractures at 18 months (4% teriparatide and 9% risedronate; p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967207
08HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, teriparatide reduced vertebral fracture incidence compared with risedronate at 18 months.
In plain wordsTeriparatide reduced vertebral fracture incidence compared with risedronate at 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral fracture incidence
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Vertebral fractures
4%
teriparatide
Vertebral fractures
9%
risedronate
Source sentences
Summary
There was a greater increase from baseline in bone mineral density at the lumbar spine (p = 0.001) and femoral neck (p = 0.02) with teriparatide compared to risedronate and a lower incidence of vertebral fractures at 18 months (4% teriparatide and 9% risedronate; p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967208
09HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, fractures were less severe with teriparatide than risedronate.
In plain wordsVertebral fractures were less severe with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral fracture severity
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
Vertebral fractures were less severe (p = 0.04) in the teriparatide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967209
10HumanRandomized controlled trialSafety outcome
In postmenopausal women with vertebral fractures, overall adverse event incidence did not differ between teriparatide and risedronate.
In plain wordsOverall adverse event rates did not differ between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOverall adverse event incidence
Study
n: not reported in source
Comparator
Risedronate 35 mg/week
Outcome group
Adverse events · Whole body
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
There was no difference in the overall incidence of adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture.
Report a problemFND-2215967210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.